NTRBW Overview

Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.

Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.

Nutriband's Product Development: Nutriband has partnered with Brand Institute to develop a worldwide brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system known as AVERSA™ FENTANYL.

Technology and Safety Features: The AVERSA™ technology aims to prevent the abuse and accidental exposure of opioids, with a strong intellectual property portfolio protecting its innovations across multiple countries.

Financial Performance: Nutriband Inc. reported a revenue increase of 50.87% year-over-year, totaling $1,289,884 for the six months ending July 31, 2025, and holds cash reserves of $6.9 million to support product development.

Product Development: The company is advancing its lead product, AVERSA™ Fentanyl, which may become the first abuse-deterrent transdermal patch globally, with potential peak annual sales estimated between $80-$200 million.

CEO Transition: Gareth Sheridan, CEO of Nutriband Inc., will temporarily step down to run for the Irish Presidential election, with Chairman Serguei Melnik taking over as interim CEO during this period.

AVERSA Fentanyl Development: Nutriband's AVERSA Fentanyl patch, designed to deter abuse and misuse, has received FDA approval for a meeting request, with potential annual US sales estimated between $80 million to $200 million.

FDA Meeting for AVERSA™ FENTANYL: The FDA has scheduled a Type C Meeting on September 18, 2025, to provide feedback on the Chemistry, Manufacturing, and Controls plans for Nutriband's AVERSA™ FENTANYL, an abuse-deterrent transdermal fentanyl patch developed in partnership with Kindeva.

Potential Impact of AVERSA™ Technology: Nutriband's AVERSA™ technology aims to enhance the safety profile of transdermal drugs by preventing abuse and accidental exposure, with projected annual US sales reaching between $80 million to $200 million while addressing global pain management needs.